Fda lifts partial clinical holds on rz358 for the treatment of congenital hyperinsulinism and authorizes u.s. inclusion in ongoing phase 3 study

Commencing study startup activities in the u.s.; participant enrollment anticipated in early 2025 commencing study startup activities in the u.s.; participant enrollment anticipated in early 2025
RZLT Ratings Summary
RZLT Quant Ranking